QCM Cayman’s Rigel Pharmaceuticals RIGL Stock Holding History

QCM Cayman’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,676	Closed	-$54K	–	180
2018 Q3	$54K	Buy	+1,676	New	+$50.3K	0.18%	116

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

QCM Cayman's RIGL Position: Q4 2018 in Review

QCM Cayman sold out of Rigel Pharmaceuticals (RIGL) in Q4 2018, closing a stake of 1,676 shares — an estimated $54K sold.

QCM Cayman first reported a position in RIGL in Q3 2018 and held it in 1 quarter. The position peaked at $54K in Q3 2018. 133 funds tracked by Wall St. Rank hold RIGL as of Q4 2018.

QCM Cayman reported no remaining Rigel Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
QCM Cayman sold 1,676 Rigel Pharmaceuticals shares in Q4 2018, an estimated $54K.
QCM Cayman first reported a position in Rigel Pharmaceuticals in Q3 2018 and held it in 1 quarter.
QCM Cayman's Rigel Pharmaceuticals position peaked at $54K in Q3 2018.
133 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2018.

Based on QCM Cayman's 13F filing for Q4 2018, filed 14 Feb 2019.